Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Cash (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Change in Cash for 11 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 94.97% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2025, up 115.49% year-over-year, with the annual reading at $15.0 million for FY2025, 115.49% up from the prior year.
  • Change in Cash hit -$1.9 million in Q4 2025 for Seres Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $153.5 million in Q3 2021 to a low of -$68.2 million in Q1 2023.
  • Historically, Change in Cash has averaged -$3.1 million across 5 years, with a median of -$21.5 million in 2022.
  • Biggest five-year swings in Change in Cash: tumbled 455.46% in 2022 and later surged 610.76% in 2023.
  • Year by year, Change in Cash stood at -$39.5 million in 2021, then decreased by 7.38% to -$42.4 million in 2022, then rose by 1.0% to -$41.9 million in 2023, then increased by 11.23% to -$37.2 million in 2024, then skyrocketed by 94.97% to -$1.9 million in 2025.
  • Business Quant data shows Change in Cash for MCRB at -$1.9 million in Q4 2025, $2.3 million in Q3 2025, and -$13.5 million in Q2 2025.